Kornimate/medical-research-clean huggingface dataset:
analysis of clinical outcomes and complications in patients received liver transplantation: a retrospective study

Conditions: Liver Transplant, Liver Cancer, Immunosuppressant

Summary: liver transplantation is the last-line method for liver failure. thomas starzl completed the first liver transplant in 1967, liver transplantation is developing rapidly. in taiwan, the first liver transplantation was started in 1984, and the living donor liver transplantation was started in 1994. according to statistics from the taiwan organ transplant registration center, from 2005 to 2018, a total of 6,211 liver transplants were completed in taiwan, and the three-year survival rate was 78.9%. the success rate of liver transplantation is closely related to the operation method, complications, the patient's conditions, and postoperative care. besides, liver cancer is the sixth most common cancer in the whole world and also the fourth leading cause of cancer-related death. approximately 90% of patients are diagnosed with liver cirrhosis at the same time when they are diagnosed with liver cancer. once the late stages of liver cirrhosis happen, the effect of treatment will be reduced. therefore, liver transplantation is the only treatment option that can solve the simultaneous occurrence of liver cirrhosis and liver cancer. since 1996, liver transplantation has been used to treat liver cancer, the organ source is always the achilles tendon of organ transplantation. therefore, milan criteria was designed to achieve the justice of organ share. however, living donor liver transplant is more popular in eastern countries because of religious factors and ethical issues and many famous medical centers are trying to expand the original milan or ucsf criteria, such as kyoto criteria and up-to-7 criteria, hoping to save more patients. however, with the expansion of conditions, the chance of recurrence or metastasis after transplantation is bound to increase. according to reports from different famous medical centers, the recurrence rate of liver cancer after liver transplantation is about 10-20%. therefore, we assume that patients with liver replacement caused by different diseases may have other postoperative conditions and complications. this study will review the preoperative diagnosis, surgical status, postoperative status, medication status, complications and recurrence of liver transplant patients in our hospital for statistical analysis.


Eligibility criteria:
inclusion criteria: * 1400 patients who received liver transplantation or patients who were followed up after liver transplantation exclusion criteria: * patients who do not meet the inclusion and exclusion criteria
the clinical impact of isolation of two different bacteria in urinary cultures

Conditions: Urinary Tract Infection

Summary: the purpose of this study is to determine whether identification of two different bacteria in urine culture of patients with indwelling catheter has a clinical impact - change in antibiotic, duration of antibiotic, days to clinical resolution and length of stay in hospital. the microbiology laboratory will randomized urine cultures with two bacteria from indwelling catheter to either reporting identity and susceptibility of the bacteria or reporting "mixed growth".


Eligibility criteria:
inclusion criteria: * adults hospitalized with indwelling urinary catheter in growth of two bacteria in urine culture exclusion criteria: * positive blood cultures or no blood cultures taken

Keywords: urinary tract infection with two bacteria in culture
investigation of the relationship between salivary histatine-5 level and vaginal candidiasis in women

Conditions: Vaginal Infection; Candidiasis

Summary: the low histatine-5 (hst-5) level of the saliva can lead to vaginal candidiasis. because hst-5 level in the saliva can effect vaginal ph, flora and local defence mechanisms. histatine-5 is secreted in the parotis and submandibular glands. i̇t riches histidine amino ascid and have antifungal activity. salivary proteins and their plasma levels were found as similar in the literature.

women with regularly menstrual cycle will enroll in the study than will separate two groups: study group: women with vaginal candidiasis ( diagnosed by clinic and lab.) control group: women ( not have any vaginal infections candida and others) saliva samples will be taken from two groups than hst-5 level will be analyzed. finally hst-5 levels of the two groups will be compared . women with diabetes, immun deficiency, pregnancy, virgin, menopausal period , premature ovarian failure will be excluded.

Eligibility criteria:
inclusion criteria: women with regularly menstrual cycle , diagnosed candidal vaginosis and not have any vaginal infection. - exclusion criteria: diabetes, immun deficiency, menopause, premature ovarian failure, pregnancy, virgin -
clinical study to evaluate safety, immunogenicity of investigational flu vaccine compared to an approved flu vaccine in children previously vaccinated in trial v118_05 (nct01964989)

Conditions: Influenza

Summary: safety, immunogenicity of an adjuvanted quadrivalent subunit influenza virus vaccine compared to non-adjuvanted comparator influenza vaccine in children previously vaccinated in trial v118_05. subjects will receive either the same or alternate type of vaccine.


Eligibility criteria:
inclusion criteria: in order to participate in this study, all subjects must meet all of the inclusion criteria described. * subject's parent/legal guardian has voluntarily given written informed consent after the nature of the study has been explained according to local regulatory requirements, prior to study entry. * male or female subject who has completed their visit 13 (study day 366 for non-naïve subjects) or clinic visit 15 (day 390 for naïve subjects) in parent trial v118_05. * for naïve subjects in parent trial v118_05 to have received two doses of the same study vaccine (i.e. 2 doses of aqiv or 2 doses of qiv). exclusion criteria: * previous immunization with any influenza vaccine (licensed or investigational) within 6 months prior to enrollment. * subjects with a clinical condition representing a contraindication to intramuscular vaccination or blood draws. * unwillingness of the parent(s)/ legal guardian(s) of the subject to refuse to participate in another clinical trial while enrolled in v118-05e3. additional eligibility criteria may be discussed by contacting the site.

Keywords: influenza vaccine mf59 adjuvant
beta-blockers in heart failure: pharmacy-level intervention comparison

Conditions: Heart Failure

Summary: the overall objective of the proposed pilot study is to begin evaluation of two methods for promoting adherence to guidelines for beta-blocker therapy in heart failure. the design includes site level baseline measurement, feedback, remeasurement after six months, and randomized (by site) comparison samples. the setting is va sites, with intervention directed at the pharmacy.

current evidence-based guidelines in va recommend one of three beta-blockers (carvedilol, metoprolol succinate, or bisoprolol) that have been shown to reduce mortality in heart failure patients with systolic dysfunction, with recommended target doses. however, pharmacy benefits management (pbm) data indicate that prescribing for beta-blockers in heart failure patients that is not in accordance with guidelines is substantial, both in terms of the agent selected and the dose. sites will be recruited and randomized to two different intensities of intervention to promote adherence to guidelines.

Eligibility criteria:
inclusion criteria: * va sites * males and females exclusion criteria: none

Keywords: adrenergic beta-antagonists guideline adherence drug prescriptions target dose
evaluation of micrornas and vitamin b12 expression in subjects with neurologic symptoms of depression, anxiety and fatigue in long covid-19

Conditions: Long COVID; Long COVID Syndrome

Summary: at the moment, the number of people with long covid is unkown because there is still no effective diagnosis. this is why is very important to analyze the most common symptoms, which are: depression, anxiety and fatigue. this project seeks to analyze some blood components of people with long covid, such as micrornas and vitamin b12, in order to identify the body processes that changed after covid-19 and thereby design better therapies and diagnostic methods focused on each of them. the hypothesis is that the expression of mir-21, -146a and -155 will be overexpressed as well as there will be a deficiency of vitamin b12 in serum in subjects suffering from long covid with neurological symptoms of depression, anxiety and fatigue.


Eligibility criteria:
inclusion criteria: * subjects with confirmed diagnosis of covid-19 by sars-cov-2 infection by pcr or antigen testing. * with presence of neurological symptoms of depression, anxiety and fatigue associated with covid-19 after three months from the first day of acute infection symptoms. exclusion criteria: * subjects who have presented symptoms of acute infection in the last twelve weeks. * subjects who present diagnostic premorbid neurological alterations. * subjects who do not have at least 2 doses of covid-19 vaccine, with last application date equal or older than 3 months.

Keywords: anxiety depression fatigue micrornas vitamin b12 long covid
a clinical trial of oral ganaxolone in women with postpartum depression

Conditions: Depressive Disorder; Depression; Depression, Postpartum; Behavioral Symptoms; Mood Disorders; Mental Disorder; Pregnancy Complications; Postpartum Blues; PPD; Postpartum Disorder

Summary: a clinical study to evaluate safety, tolerability and efficacy of oral administration of ganaxolone in women with postpartum depression


Eligibility criteria:
inclusion criteria: * experiencing a major depressive episode, which started between the start of the third trimester and 4 weeks following delivery. the major depressive episode must be diagnosed according to mini international neuropsychiatric interview (mini) 7.0 interview * given birth in the last 6 months * hamd17 score of ≥ 20 at screening but \< 26 * must agree to stop breastfeeding from start of study treatment or must agree to temporarily cease giving breast milk to her infant(s) exclusion criteria: * current history of any psychotic illness, including major depressive episode with psychotic features * history of suicide attempt within the past 3 years * history of bipolar i disorder * history of seizure discorder

Keywords: postpartum care postpartum depression
use of hyoscyamine versus tamsulosin for management of ureteral stent irritation

Conditions: Lower Urinary Tract Symptoms

Summary: the objective of this project is to compare the efficacy of hyoscyamine to tamsulosin monotherapy in treating lower urinary tract symptoms in patients with indwelling double-j ureteral stents.

ureteral stents are routinely used in a variety of urologic conditions. unfortunately, indwelling ureteral stents commonly cause significant pain and discomfort due to irritation to the urinary system. many studies have looked at methods to reduce these uncomfortable symptoms ranging from altering stent designs to pharmacologic therapies attempting to alleviate stent-discomfort. however, stent-related discomfort continues to be an issue and is often the cause of their removal earlier than planned. while the efficacy of certain alpha blockers and anticholinergics in treating stent-related symptoms have been studied, the data for the use of hyoscyamine in this setting is lacking. a literature search yielded no studies evaluating the use of hyoscyamine in this setting to date. the investigators hypothesize that hyoscyamine (brand name levsin) is equivalent to tamsulosin in treating lower urinary tract symptoms in patients with indwelling double-j ureteral stents due to its anticholinergic properties. furthermore, the investigators hypothesize that patients in the hyoscyamine arm will not require additional pain medications (e.g. pyridium, narcotics) to help control stent-related discomfort compared to the tamsulosin arm.

Eligibility criteria:
inclusion criteria: * patients must be 18 years of age or older * patient must require placement of a ureteral stent(s), per standard of care, following routine urological procedures including, but not limited to, ureteroscopy, stone extraction, or management of upper tract transitional cell carcinoma * patient must agree to abstain from other clinical studies during the study period exclusion criteria: * patients younger than 18 years of age * patients with chronic or pre-existing indwelling stents * patients currently receiving anticholinergic or alpha blocker therapy * patients with chronic opioid or analgesic usage * patients with chronic pain syndrome or symptomatic benign prostatic hyperplasia * patients with an active untreated urinary tract infection * patients who are currently pregnant or nursing * patients with allergies or contraindication to either tamsulosin or hyoscyamine * patients on active chemotherapy * patients currently receiving other investigational therapy * patients who are unable to sign consent/answer questionnaire due to compromised mental capacity or language barrier (the questionnaire is not validated in other languages) * patients who have a stent placed emergently for an obstructing stone or septic stone without immediate stone removal, * any stents placed that will stay in for longer than 2 weeks
a study to test whether bi 3032950 helps people with ulcerative colitis

Conditions: Ulcerative Colitis

Summary: adults between 18 and 80 years of age with ulcerative colitis can participate in this study. this is a study for people for whom previous treatment was not successful or who stopped previous treatment. the purpose of this study is to find out whether bi 3032950 helps people with ulcerative colitis. this study has 2 parts. in part a, participants get bi 3032950 as an infusion into a vein every 4 weeks. after 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improved. before the results of this assessment are available, participants move on to part b and get bi 3032950 as an injection under the skin. participants whose results show clinical response after 12 weeks can continue treatment with bi 3032950. they get bi 3032950 injections under the skin every 4 weeks for up to 2 years. participants visit their doctors every 4 weeks. during these visits, the doctors check the signs and symptoms of ulcerative colitis. this includes taking blood and stool samples. doctors also do endoscopies. this is a procedure that uses a tube with a camera to look inside the body. the doctors also regularly check participants' health and take note of any unwanted effects.


Eligibility criteria:
inclusion criteria * female and male participants aged 18 to 80 years (inclusive) at the time of informed consent, * diagnosis of ulcerative colitis (uc) ≥3 months prior to screening by clinical and endoscopic evidence corroborated by a histopathology report, * inadequate response, loss of response, or intolerance to treatment with biologic/targeted therapy or termination of treatment with biologic/targeted therapy for any other reason, * female participants of childbearing potential must be ready and able to use highly effective methods of birth control and male participants are required to use condoms, * further inclusion criteria apply. exclusion criteria * diagnosis of indeterminate colitis, ischemic colitis, radiation colitis, diverticular disease associated with colitis, microscopic colitis, or crohn's disease (cd), * findings suggestive of cd (e.g. fistulae, granulomas on biopsy), * evidence of colonic moderate/severe mucosal dysplasia or colonic adenomas, unless properly removed, * gastrointestinal neoplasia, primary sclerosing cholangitis, or known colonic stricture, * evidence of fulminant colitis or toxic megacolon at screening, * current ileal-pouch anal anastomosis, ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine, * previous surgery or anticipated surgical intervention for uc (trial participants with previous colonic surgery may be allowed based on investigator's judgement after discussion with the sponsor), * any current or prior abscesses, unless they have been drained and treated at least 6 weeks prior to first trial drug administration and are not anticipated to require surgery, * further exclusion criteria apply.
breast cancer - navigate - prospective cohort

Conditions: Breast Cancer; Quality of Life; Chemotherapy

Summary: the chrysalis initiative (tci) has with its technology partner eversana/intouch developed the bc-navigate website/application to help guide women through care delivery during breast cancer treatment. tci a nonprofit, breast cancer education and navigation organization is developing methods to address health inequities in cancer care delivery. tci and its new academic/clinical partner, the robert h. lurie comprehensive cancer center of northwestern university, propose to apply tci's developed patient navigation support techniques to enhance knowledge and self-advocacy among a cohort of black and african american women, and other women of color (woc), receiving care in northwestern's breast cancer program. therefore, the purpose of this study is to apply tci's patient navigation-and-coaching program and its website/mobile app (breast cancer-navigate) platform to improve timely initiation to patient adjuvant treatment among woc breast cancer patients and evaluate the feasibility and preliminary efficacy of this approach.


Eligibility criteria:
inclusion criteria: * 18 years of age and older * diagnosed with non-metastatic breast cancer (stages i-iii) * an order placed for a post-operative chemotherapy cycle by a nm clinician * not have initiated a recommended post-operative chemotherapy cycle at the time of study enrollment * completed surgery for breast cancer * first-time diagnosis of breast cancer * established care at northwestern medicine * english-speaking as the navigation website is not yet available in other languages * access to internet on a smart phone or computer/tablet * any ethnic background * we will only consider patients that sign an informed consent form exclusion criteria: * men will be excluded because the navigation website only contains content and resources for women. men also make up less than 1% of all breast cancer diagnoses and the breast cancer-navigate app/website content was developed for female breast cancer patients. * diagnosis of additional, life-threatening condition (e.g., end-stage renal disease, heart failure) which can interfere with timely planned adjuvant chemotherapy treatment for cancer.

Keywords: ehealth
evidence for fusion in spine with orthoss®

Conditions: Lumbar Spondylolisthesis Involving L4-L5; Lumbar Spondylolisthesis Involving L5-S1; Lumbar Spinal Stenosis; Lumbar Disc Degeneration

Summary: this study aims to evaluate the performance and safety of the orthoss® as a bone graft extender in lumbar spondylodesis involving 1-2 levels (l4-l5 and/or l5-s1).

this clinical investigation is a prospective, non-interventional, uncontrolled clinical trial, organized to generate clinical data on performance and safety of orthoss® as a bone graft extender mixed with local bone at ratio of 1:1 and pedicle bone marrow aspirate in lumbar spondylodesis involving 1-2 levels. (orthoss® is ce marked for this indication). if you as a patient have a wear and tear disease of the spine, an operation serves to restore the stability of the spinal column. in order to promote a bony build-up of the lumbar spine segment (fusion), bone replacement material is used in your case as standard. the aim of this observational study is to determine fusion in order to address clinical performance of that bone replacement material.

Eligibility criteria:
inclusion criteria: * the patient (male or female) must be 18 years or older * the patient must be a candidate diagnosed with either degenerative disc disease including 1-2 level (l4-l5 and/or l5-s1) or dysplasic spondylolisthesis (degree 1 or 2) or lumbar stenosis * if the patient is of child-bearing potential, the patient confirms not to be pregnant * the patient is able to comply with the clinical investigation-related procedures such as attending all follow-up procedures * the patient is able to fully understand the nature of the proposed surgery and is able to provide a signed informed consent including the use of the anonymized data for scientific publication * the patient will not participate in another clinical investigation during this clinical investigation exclusion criteria: * general contraindications for surgical treatment are present * the patient has a history of malignancy, radiotherapy, or chemotherapy for malignancy within the past five years * the patient is currently being treated with radiation, chemotherapy, immunosuppression or steroid therapy dose equivalent of more than 5mg prednisolon * the patient is pregnant or nursing * women of childbearing age who are not using a highly effective method of birth control * the patient has acute or chronic infection at the surgical site * the patient has a known allergy to bovine bone material * the patient has a medical history of alcohol or drug abuse within the last year prior to the screening examination * vulnerable population * patient is currently participating, or has participated in another clinical investigation within 6 months
study of shr-8068 combined with adebrelimab and platinum-containing chemotherapy in the treatment of advanced gastric and esophageal cancer

Conditions: Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma

Summary: objective response rate (orr) was evaluated to evaluate the efficacy of shr-8068 combined with adebrelimab and platinum-containing chemotherapy in first-line treatment of advanced gastric and esophageal cancer.


Eligibility criteria:
inclusion criteria: 1. volunteer to join the clinical study, and sign the informed consent, compliance is good, can cooperate with follow-up; 2. aged 18-75 at the time of signing the informed consent; 3. histologically or cytologically confirmed, unresectable, advanced or recurrent/metastatic adenocarcinoma of the gastric or gastroesophageal junction, or unresectable or recurrent/metastatic esophageal squamous cell carcinoma without radical chemoradiation; 4. at least one measurable lesion consistent with recist v1.1; 5. ecog ps score: 0-1; 6. the organ function level is good; exclusion criteria: 1. her2-positive patients; 2. untreated (radiation or surgery) central nervous system metastasis, or accompanied by meningeal metastasis, spinal cord compression, etc.; 3. uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion with clinical symptoms; 4. previous or co-existing malignant neoplasms; 5. the presence of any active or known autoimmune disease; 6. people who have previously received an organ transplant; 7. have clinical symptoms or diseases of the heart that are not well controlled; 8. known allergic reactions to adebrelimab or other monoclonal antibodies or investigational drugs;